Drug profile · INN
saxagliptin
ONGLYZA
saxagliptin (ONGLYZA) is an FDA-listed pharmaceutical active ingredient. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Drug details — saxagliptin
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
saxagliptin (ONGLYZA) is an FDA-listed pharmaceutical active ingredient. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is saxagliptin?
saxagliptin (ONGLYZA) is an FDA-listed pharmaceutical active ingredient. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for saxagliptin?
ONGLYZA is a marketed brand name for saxagliptin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of saxagliptin?
saxagliptin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.